Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise make Weight-Loss drugs work better?

NCT ID NCT07319975

Disease control Sponsor: Istanbul Galata University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two popular weight-loss drugs, semaglutide and tirzepatide, alone or combined with exercise, in 48 adults with obesity. The goal is to see which approach better reduces body fat while preserving muscle mass, and improves strength and metabolic health. Participants will be followed for changes in body composition, muscle strength, and other health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide and tirzepatide
What this could lead to
If successful, this could show that adding exercise to these weight-loss drugs helps preserve muscle while losing fat, leading to better overall health.
What could go wrong
This is a small, early-stage study with only 48 participants, so results may not apply to everyone. The drugs can cause side effects like nausea and vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Those between the ages of 25 and 60 years * Those with a body mass index (BMI) between 30 and 40 kg/m2 according to the World Health Organization (WHO) classification * Individuals who volunteered to participate in the study Exclusion Criteria: * Individuals with a BMI greater than 40 kg/m2 according to the WHO classification * Individuals with a Charlson comorbidity index score of 3 or higher * Uncontrolled arrhythmia, hypertension, heart failure, diabetes, and unstable angina pectoris * Cooperation impairment, orthopedic, and neurological problems that may interfere with evaluation and treatment * Individuals with a history of lower extremity injury or surgery in the last six months * Diagnosed with diabetes and complications such as nephropathy, retinopathy, and neuropathy * Individuals with concomitant chronic respiratory disease * Individuals with acute infections * Individuals with middle ear pathologies (such as tympanic membrane rupture, otitis media) * Individuals with a history of spontaneous or trauma-related pneumothorax * Smokers * Pregnancy * Individuals with a STOP-bang score of 3 or higher * Individuals on a structured diet program for weight loss during the study period * Individuals who have had endoscopic intervention and/or bariatric surgery within the last year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Biruni University

    Istanbul, Zeytinburnu, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.